31 artigos
Orforglipron approved 294 days ahead of schedule for obesity treatment, marking first drug under new priority voucher system.
Avlayah becomes the first treatment targeting neurologic symptoms of rare genetic disorder affecting 500 Americans.
New targeted therapy offers hope for patients with specific genetic mutations in non-small cell lung cancer.
Two breakthrough approvals target Hunter syndrome brain complications and cerebral folate deficiency for the first time.
New GLP-1 drug Foundayo gets fastest FDA approval since 2002, targeting obesity and metabolic health through appetite control.
Foundayo and Zepbound receive rapid FDA approval for chronic weight management in adults with obesity or weight-related conditions.
FDA approves Foundayo (orforglipron) and Zepbound (tirzepatide) for chronic weight management in adults with obesity or overweight conditions.
